You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

371 Results
Regimen
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    dexamethasone
Aug 2024
Regimen
Intent: Palliative
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal)
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Apr 2024
Regimen
Regimen
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
Exceptional Access Program
    everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
Jun 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Chronic Lymphocytic Leukemia
Nov 2024

Pages